Literature DB >> 26305036

Chemotherapy: Rolapitant—a new and safer antiemetic agent.

Diana Romero.   

Abstract

Year:  2015        PMID： 26305036     DOI： 10.1038/nrclinonc.2015.144

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.

Authors:  Lee S Schwartzberg; Manuel R Modiano; Bernardo L Rapoport; Martin R Chasen; Cesare Gridelli; Laszlo Urban; Allen Poma; Sujata Arora; Rudolph M Navari; Ian D Schnadig
Journal:  Lancet Oncol       Date:  2015-08-10       Impact factor: 41.316

2.  Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.

Authors:  Bernardo L Rapoport; Martin R Chasen; Cesare Gridelli; Laszlo Urban; Manuel R Modiano; Ian D Schnadig; Allen Poma; Sujata Arora; Vikram Kansra; Lee S Schwartzberg; Rudolph M Navari
Journal:  Lancet Oncol       Date:  2015-08-10       Impact factor: 41.316
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.